Objective: To investigate the relationship between NF-B activity, cytokine levels, and pain sensitivities in a rodent model of osteoarthritis (OA).
Introduction
Knee osteoarthritis (OA) is a leading cause of disability with large associated economic costs. It is anticipated that 20% of adults will be affected by pain or disability associated with OA by the year 2030 (1). At the tissue level, the disease is associated with cartilage degradation, synovial hypertrophy, and subchondral bone remodeling. C linically, the disease is diagnosed by radiographic changes that include joint space narrowing, presence of osteophytes, and synovial hypertrophy. W hile patients present with j oint pain and impaired joint m obility (2) , the mechanistic link between these behaviors and tissue level changes are poorly understood (3) (4) (5) .
Direct or indirect interactions of inflammatory cytokines (e.g. TNF-α, IL-1β, IL-6) with knee joint afferents has been suggested as a possible contributor to pain in arthritis (6) .
The inflammatory cytokines TNF-α and IL-6 have been demonstrated to play a direct role in sensitization of nociceptors and the development of mechanical allodynia in preclinical models of inflammatory arthritis (7, 8) . Elevated levels of these pro-inflammatory cytokines have been observed in human OA patients (6, 9, 10) , while TNF-α and IL-1β antagonism may lead to substantial reductions in pain scores for patients presenting with an inflammatory component of osteoarthritis (11) (12) (13) . While the presentation of inflammation may vary widely across patients with OA and even within the time course of OA pathology, it is now thought that inflammatory cytokines play a key role in pain development in OA.
A key regulator of TNF-α, IL-1β, and IL-6 is the transcription factor nuclear factor kappa-lightchain-enhancer of activated B cells (NF-κB). The NF-кB transcription factor family induces the expression of more than 150 genes that play a role in immunity, inflammation, anti-apotosis, cell proliferation, and the negative feedback of NF-кB (14) (15) (16) (17) . NF-кB activity can be induced by multiple cellular stimuli including inflammatory cytokines (e.g. TNF-α and IL-1β), extracellular matrix degradation products, and mechanical overload. Once activated, NF-кB induces target gene expression in multiple cell types including synoviocytes, chondrocytes, and fibroblasts (18) (19) (20) . In arthritis, NF-кB activity is associated with increased expression of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6), metalloproteinases, chemokines, and inducible enzymes (COX-2) (21) (22) (23) (24) . Although its role in pain in arthritis is not completely understood, the inhibition of key mediators of the NF-κB activation pathway leads to a reduction in pain in rodent models of arthritis (25, 26) , suggesting that regulation of these key mediators is the means by which NF-кB facilitates the development and propagation of pain in arthritis.
Carlsen and co-workers previously described the use of a transgenic NF-кB-luciferase reporter mouse to study the transient kinetics of NF-кB activation after UVB radiation exposure and collagen-antibody induced arthritis (17, 27) . This transgenic mouse contains NF-кB response elements upstream of the firefly luciferase gene, which allows NF-кB activity to be noninvasively and longitudinally quantified via luminescent imaging; this has been used to demonstrate NF-кB inhibition using a small molecule inhibitor of IKK-2 in a model of collagen antibody-induced arthritis (28) .
For its repeatability and rapid onset of pathology, intra-articular injection of mono-iodoacetate (MIA) has been widely used to induce arthritis (26, (29) (30) (31) (32) (33) (34) (35) (36) (37) . Injection of MIA into the joint inhibits glycolysis in chondrocytes, which results in chondrocyte cell death. As a result, changes resembling human OA that include proteoglycan loss, collagen fibrillation, and subchondral bone remodeling, progress rapidly over a 4-6 week period (29-34, 37, 38) . A biphasic pain response has been documented in the MIA model that includes an early inflammation-associated pain phase followed by a late non-inflammatory pain phase (36, 37) . The MIA model is of great interest for studying the transient role of NF-кB activity and cytokine levels in contributing to both inflammatory and non-inflammatory pain in a model of OA.
In the present study, in vivo luminescent imaging of NF-кB activity was used to investigate the relationship between NF-кB activity, serum cytokines, and pain sensitivities in the rodent model of MIA-induced OA. This model was evaluated to test whether in vivo luminescent imaging could provide a spatially accurate measure of NF-кB activity in the knee joint and to test its relationship to development of disease.
Method

Intra-articular Injections and Experimental Timeline
The transgenic mice used for this study were engineered to carry cDNA for firefly luciferase downstream of NF-kB response elements (n=24, BALB/c-Tg(NFκB-RE-luc), age 7-8 weeks;
Taconic Farms Inc., Hudson, NY). All procedures were performed with approval of the Duke University IACUC. Following a 1-week acclimation period, under anesthesia (2% isoflurane inhalation), mice received intra-articular knee injections via 30-gauge needle of MIA (5 μl, 10 mg/ml, n=12) or saline as a control (5 μl, n=12). One set of animals (n=6/group, Saline and MIA) was sacrificed on day 3 and a second set of animals was sacrificed on day 28 (n=6/group, Saline and MIA). 
Ex Vivo NF-B Activity Luminescent Imaging
Immediately post sacrifice, the ipsilateral and contralateral tibiofemoral knee joints, patella, and adjacent muscle tissue were harvested for immediate ex vivo luminescent imaging in a subset of animals (n=18). Tissue was placed in separate wells of a 12-well tissue culture plate and each well was supplemented with 300 μg/ml D-luciferin in Dulbecco's Phosphate-Buffered Saline (Gibco, Grand Island, New York). After 5 minutes, the tissue culture plate was imaged as for the whole body on the IVIS100 (Perkin Elmer; 15 second exposure). Selected ROI around each tissue was measured as photons/sec/cm 2 (LUM KNEE , LUM PATELLA , LUM MUSCLE ).
Pain-related Sensitivity (Mechanical Allodynia)
Mice were acclimated to a wire-bottom cage and exposed to the von Frey testing procedure over 
Weight-Bearing
Mouse hind-limb weight-bearing was determined using an incapacitance meter (IITC Life Science Inc., Woodland Hills, CA). Mice were placed in an angled plexiglass chamber with the two hind paws resting on two independent force plates, the front paws resting on the plexiglass ramp, and the mouse facing forward. Force (gram-force) readings were obtained over a 3 second interval for both the ipsilateral (WB ipsi ) and contralateral (WB contr ) limb; three independent measurements were obtained for each mouse at each time point and averaged. Percentage weight-bearing was normalized (N WB ) by dividing the weight-bearing on the ipsilateral limb by the total weight-bearing for both hindlimbs according to equation 3,
Serum Cytokines
The following serum cytokine concentrations were quantified using multiplex and single immunoassays (Mouse Pro-inflammatory 7-plex and Mouse MCP-1 single-plex, Meso Scale Discovery, Rockville, MD): interleukin-1 beta (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12p70 (IL-12p70), chemokine C-X-C motif ligand 1 (CXCL1), tumor necrosis factor-alpha (TNF-), interferon-gamma (IFN-), and monocyte chemotactic protein-1 (MCP-1).
Measurements were performed on a SECTOR Imager 2400 (Meso Scale Discovery, Rockville, MD). The mean intra-assay CVs for the 7-plex pro-inflammatory and MCP-1 immunoassay were 3.3% and 2.8%, respectively. The lower limit of detection (LLOD) for each cytokine is as follows: IL-1 (0.21 pg/ml), IL-6 (3.07 pg/ml), IL-10 (0.37 pg/ml), IL-12p70 (9.73 pg/ml), CXCL1 (0.27 pg/ml), TNF- (0.63 pg/ml), IFN- (0.06 pg/ml), and MCP-1 (1.46 pg/ml). One half of the LLOD was used for any value below the level of detection for the purpose of performing statistical analyses. Concentrations of serum TNF- and IL-12p70 were below the LLOD in a majority of samples and so were not included in the analysis.
Histology
Both ipsilateral and contralateral limbs were dissected to remove excess skin and musculature while preserving the knee joint capsule. The intact joints were fixed in 10% formalin for 3 days, decalcified for 5 days in Cal-EX Decalcifying Solution (Fisher Scientific, Hampton, NH), and embedded in paraffin. Sections (8 μm thick) were taken in the coronal plane within the loadbearing region of the joint and mounted at 80 μm intervals. Three slides covering the central sections of each joint were stained with Safranin-O and fast green. A single section representing the most severe evidence of arthritic changes was selected for each joint and was scored according to a modified Mankin scoring system (40) . Images were randomized and two blinded scorers (BAM, RDB) assigned grades, by consensus, to the tibial and femoral cartilage in the medial and lateral compartments. Ordinal scores were assigned for 7 parameters related to degeneration including cartilage structure (score range 0-11), loss of Safranin-O staining (range 0-8), tidemark duplication (range 0-3), fibrocartilage formation (range 0-2), chondrocyte clones in uncalcified cartilage (range 0-2), hypertrophic chondrocytes in calcified cartilage (range 0-2), and subchondral bone thickness (range 0-2). Scores were summed for the lateral femur, medial femur, lateral tibia, and medial tibia to arrive at a maximum score of 120 for each knee.
Statistics
All statistical analyses were performed using JMP Pro (JMP, Cary, NC). Continuous, normally To test for relationships that were specific to pain phase (early (day3) or late (day28)), additional multivariate linear regressions were performed to test for an association of 50% withdrawal threshold (N 50%WT ) with independent variables (N LUM , IL-6, IL-1, and IL-10) at day 3 or 28.
Significance of the regression was reported with a Bonferroni correction of α = 0.0125 (0.05/4) applied for both days 3 and 28. Linear regression was performed to test for an association of weight-bearing (N WB ) at day 3 or day 28 with independent variables (N LUM , IL-6, CXCL1, and MCP-1). Significance of the regression was reported α = 0.0125 (0.05/4) for both days 3 and 28.
Independent variables were log-transformed (base-10) prior to statistical analysis.
Results
NF-B Activity in MIA
A transient increase in NF-B activity luminescence (N LUM ) (~4-5 fold) was observed following MIA injection into the knee joint ( Figure 1B and C) . Luminescence was observed consistently and broadly distributed in the MIA injected limb on day 1. Over time, the intensity of luminescence, which peaked at the knee ROI day 1 post-injection, slowly and steadily declined thereafter ( Figure 1B ). For MIA injected knees, luminescence (N LUM ) was significantly increased in the knee ROI compared to pre-injection values on days 1 (p<0.0001) and 3 (p<0.0001; ANOVA) ( Figure 1C ), but returned to pre-injection levels by day 28. Additionally, luminescence (N LUM ) was significantly increased in MIA injected knees compared to saline injected knees on day 3 (p=0.043; ANOVA).
Ex Vivo NF-B Activity Luminescent Imaging
In vivo luminescence (LUM ROI ) was significantly correlated to the ex vivo tibiofemoral knee luminescence (LUM KNEE ) (R 2 = 0.71, p<0.0001), and ex vivo patella luminescence (LUM PATELLA ) (R 2 = 0.52, p<0.0001), with evidence of weaker correlations to ex vivo muscle luminescence (LUM MUSCLE ) (R 2 = 0.16, p<0.016) (Figure 2 ). This observation confirms the tibiofemoral knee as the primary source of in vivo NF-κB generated luminescence.
Serum Cytokines
Serum levels of IL-6 were transiently increased following MIA injection into the knee joint ( Figure 3) . Serum IL-6 was significantly increased in MIA injected animals compared to saline injected animals on day 3 (p=0.004) and significantly increased on day 3 compared to day 28 in MIA injected animals (p<0.0001; Friedman Test). There was no evidence of between group or time-related differences in serum cytokines CXCL1, MCP-1, IFN-, IL-1, IL-10 (p > 0.05;
Friedman Test).
Histological Evidence of Arthritis
Histological scoring indicated that MIA injected knees showed the greatest change in proteoglycan loss, fibrillation/clefts of the articular cartilage surface, and hypertrophic chondrocytes in the calcified cartilage ( Figure 4A ). On day 28, there was evidence of statistically significant differences in the total modified Mankin score in MIA injected limbs compared to saline injected limbs (p=0.005; Friedman Test) ( Figure 4B ).
Behavioral Assessments
MIA knee injection resulted in the induction of significantly elevated sensitivity to mechanical withdrawal threshold (N 50%WT ) were strongly negatively correlated (r = -0.78, p=0.0029) on day 3, serum IL-6 and N 50%WT were strongly negatively correlated (r=-0.67, p=0.011) on day 3, and serum IL-1 and N 50%WT were strongly negatively correlated (r=-0.72, p=0.0088) on day 28
( Figure 6B ). NF-B activity (N LUM ) and ipsilateral weight-bearing (N WB ) were also strongly negatively correlated (r=-0.71, p=0.012) on day 3 ( Figure 6C ).
Discussion
We used luminescent imaging to investigate the relationship between NF-B activity, cytokine levels, and pain sensitivities in a rodent model of OA. The tibiofemoral knee appeared to be the principal source of NF-κB related luminescence following MIA injection, and revealed strong relationships between local measures of NF-κB activity, pain sensitivity, and systemic measures of IL-6. These findings establish luminescent imaging of NF-B activity as a novel imaging biomarker of pain-related sensitivities in a rodent model of OA.
Injection of MIA into the NF-B-luc reporter mice produced both histological and behavioral changes associated with the development of arthritis (26, 35) . Significant histological changes were observed in the MIA injected knees by day 28. A biphasic pain response was observed with an acute increase in mechanical sensitivity followed by a persistent increase in MIA injected limbs compared to saline control limbs on days 21 and 28. Similar biphasic pain responses that include an early inflammation associated pain phase and a late non-inflammation associated pain phase have been reported in weight bearing and spontaneous mobility in the MIA model (36, 37) . Thus, the biphasic response observed in the mechanical sensitivity data is consistent with these previous pain-related behavioral measures.
The biphasic response has been reported in the rat model at moderate MIA injection concentrations (6 -60 mg/ml) (36, 37) , while high concentrations (50-100 mg/ml) produce a pain response that is characterized by rapid onset, no recovery, and is sustained chronically in both mice and rats (33, 44, 45) . The concentration used within this study (10 mg/ml) was within the range expected to produce a biphasic pain response. It is important to note that, while present, the late pain phase observed in this study was moderate and was only observed in the mechanical allodynia measure. A more severe chronic pain response in both mechanical allodynia and weight bearing would have likely been observed at higher concentrations of MIA injection.
Luminescent in vivo imaging provides a powerful tool to non-invasively quantify molecular events during musculoskeletal disease progression and therapeutic intervention. NF-B activity was observed in the ex vivo tibiofemoral knee and patella with a strong correlation with the in vivo ROI luminescence measurements. The ex vivo imaging established the tibiofemoral knee, and to a lesser extent the patella, as the sources of the in vivo total knee ROI luminescence. In vivo luminescent imaging as used here, provided a spatially accurate measure of NF-B activity in the knee that may be useful for the rapid screening of NF-B targeting therapeutics for the treatment of OA and other inflammatory pathologies (18, 42) .
MIA injection induced a transient increase in NF-B activity that preceded histological changes in the knee. Immediately post injection, elevated NF-B activity was observed throughout the limb on day 1, which localized to the knee by day 3, and returned to pre-injection levels by day 28. This pattern was consistent with the pattern previously reported for MIA injection, namely an inflammatory response in the first 1-3 days post-injection, followed by a subsequent dissipation of inflammation (29, 30) . Additionally, NF-B activity has been demonstrated during inflammation in models of collagen-induced and adjuvant-induced arthritis (28, 43) . A peak in joint swelling at day 1, a peak in synovial hyperplasia at day 3, and synovial inflammatory cell invasion characterizes this inflammatory response through day 3 in the MIA model. It is possible that the day 3 time point chosen for this study may have missed the peak levels of inflammation and pain sensitivity, but the elevated NF-κB activity/IL-6 levels at day 3
indicate that this time point falls within the inflammatory period of this model. Our data suggest that the primary role of NF-B in the MIA model is as a mediator of the early inflammatory response and may suggest that NF-B targeted therapeutics would be most effective during the early developmental phases of OA.
In this study, luminescent imaging of NF-B activity and NF-B regulated serum cytokines were validated as biomarkers of pain-related sensitivities in the MIA model. NF-B activity was very strongly correlated to mechanical allodynia and was the only measure with significant correlation to mechanical allodynia when analyzed independently of pain phase. A linear model was constructed that was capable of predicting ~67% (Q 2 ) of the variability in the mechanical allodynia data, which included luminescent imaging of NF-B activity, serum IL-6, serum IL-1β, and serum IL-10 as predictive variables. NF-B activity was determined as the most important variable in the model according to VIP. When these measures were correlated to mechanical allodynia by pain phase, NF-B activity and serum IL-6 were strongly correlated to mechanical sensitivities in the early pain phase and IL-1β was strongly correlated to mechanical sensitivities in the late pain phase. These data support the presence of an early inflammatory pain phase and a late non-inflammatory pain phase in the MIA model of OA and suggests distinct biomarkers can distinguish the two phases. It may indicate a distinct role for the NF-B /IL-6 pathway in the acute pain sensitivities in arthritis and IL-1β in chronic pain sensitivities associated with joint/cartilage destruction. This is consistent with previous findings that both IL-6 and IL-1β are associated with increased pain sensitivities in the rodent knee joint (7, 46) . (significant correlations denoted by *)
